cediranib + cisplatin + S-1

Combination therapy of **cediranib**, **cisplatin**, and **S-1** is an investigational anti-cancer regimen for advanced gastric cancer and potentially other solid tumors. Cediranib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs), impeding tumor angiogenesis. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis. S-1 is an oral fluoropyrimidine derivative comprised of tegafur, gimeracil, and oteracil, primarily inhibiting thymidylate synthase to disrupt DNA synthesis. This triple regimen is being evaluated for safety and efficacy, showing tolerability and preliminary anti-tumor activity in phase I trials for advanced gastric cancer[1][2][4].